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Pevonedistat (MLN4924), a specific NEDD8-activating enzyme inhibitor, has been considered as a promising treatment for glioblastoma,
which is currently in Phase I/II clinical trials. On the other hand, inhibition of neddylation pathway substantially upregulates the
expression of T cell negative regulator programmed death-ligand 1 (PD-L1), which might account for the potential resistance via evasion
of immune surveillance checkpoints. Whether administration of anti-PD-L1 enhances the efficacy of pevonedistat through a cytotoxic T
cell-dependent mechanism in glioblastoma needs to be investigated. Here, we report that depletion of neddylation pathway key
enzymes markedly elevates PD-L1 expression in glioblastoma cancer cells. Consistently, neddylation inhibitor pevonedistat significantly
enhances PD-L1 expression in both glioblastoma cancer cell lines and animal models. Mechanistically, pevonedistat increases PD-L1
mRNA levels mainly through inhibiting Cullin1-F-box andWD repeat domain-containing 7 E3 ligase activity and accumulating c-MYC
proteins, a direct transcriptional activator of PD-L1 gene expression. In addition, inhibition of Cullin3 activity by pevonedistat also
blocks PD-L1 protein degradation. Importantly, pevonedistat attenuates T cell killing through PD-L1 induction, and blockade of PD-L1
restores the sensitivity of pevonedistat-treated glioblastoma cancer cells to T cell killing. The combination of pevonedistat and anti-PD-L1
therapy compared to each agent alone significantly increased the therapeutic efficacy in vivo.Our study demonstrates inhibition of
neddylation pathway suppresses cancer-associated immunity and provides solid evidence to support the combination of pevonedistat
and PD-L1/programmed cell death protein 1 immune checkpoint blockade as a potential therapeutic strategy to treat glioblastoma.
Introduction
Glioblastoma multiforme (GBM), arising from malignant glial
cells (such as astrocytes and oligodendrocytes), is the most com-
mon and lethal form of brain tumor. In addition, GBM accounts
for more than half of all primary brain tumors.1 Despite survival
benefits have been improved by current treatment, median sur-
vival remains just only more than 1 year (12~15 months) after
standard surgery followed by fractionated radiotherapy and
temozolomide.2 Since GBM is frequently refractory to current
chemotherapy/radiotherapy regimes, there is a dire need to
improve treatment options for GBM.
Protein neddylation is a post-translational modification pro-
cess by which the ubiquitin-like protein NEDD8 is conjugated to
its target proteins.3 This process is catalyzed by three enzymes in a
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sequential action: the E1 NEDD8-activating enzyme (NAE), con-
sisting of NAE1 (APP-BP1) and UBA3 (ubiquitin like modifier
activating enzyme 3) heterodimer; the E2 NEDD8-conjugating
enzymes (UBC12/UBE2M and UBE2F) and the E3 NEDD8
ligases.4 The neddylation pathway has been identified to be over-
activated in a majority of GBM tumor tissues compared to normal
tissues.5 Pevonedistat (MLN4924) is a first-in-class NAE inhibitor,
which has been recently considered as an attractive anticancer
agent and has shown a significant therapeutic effect in some Phase
I clinical cancer trials.6,7 Pevonedistat treatment largely blocks cul-
lin neddylation and inhibits cullin-RING E3 ligase activity, and in
turn leads to the accumulation of tumor suppressor substrates to
induce cell-cycle arrest, senescence or apoptosis in GBM cells.
Additionally, pevonedistat orthotopically suppressed tumor
growth in a xenograft model of human GBM.5 Several combina-
tions of pevonedistat and anticancer agents have been proposed to
enhance the cytotoxic effect of pevonedistat.8–12 Thus, developing
a rational combination therapy with pevonedistat may improve
anticancer strategy.
In the past decade, some major breakthroughs have been
achieved in our understanding of cancer cell immunosuppression.
Multiple inhibitory ligands expressed on the surface of tumor cells,
notably programmed death-ligand 1 (PD-L1), are shown to be key
molecules in cancer immune evasion. Interaction of PD-L1 with the
programmed cell death protein 1 (PD-1) receptor on T cells leads to
reduced T cell proliferation, cytolytic activity and cytokine release.
Therefore, PD-1/PD-L1 antibodies block the co-inhibitory ligation
and restore T cell function.13,14 The checkpoint blockade immuno-
therapies (such as nivolumab and atezolizumab) have been
approved by FDA for the treatment of multiple types of cancer.15,16
In GBM, higher PD-L1 expression has been correlated with poorer
patient prognoses,17 suggesting that PD-L1 does suppress anti-
tumor immunity in some patients. In addition, case reports have
indicated that anti-PD-1 therapy is effective for some patients with
GBM.18 A few of ongoing clinical trials, including nivolumab mon-
otherapy as well as combination with temozolomide or radiother-
apy, are exploring the efficacy across different lines of treatment in
GBMpatients.
Accumulating evidence demonstrates that some conventional
and targeted cancer therapies modulate antitumor immunity,19,20
suggesting combination of cytotoxic anticancer agents with
immune checkpoint blockade treatment might lead to promising
combinatorial regimens. In the current study, we find genetic and
pharmacologic inhibition of neddylation pathway significantly
increases PD-L1 expression in GBM cancer cells. Protein
neddylation inhibitor pevonedistat enhances PD-L1 transcription
by inactivating SKP1-Cullin1-F-box and WD repeat domain-
containing 7 (FBXW7) activity and blocking c-MYC protein deg-
radation, which turns on PD-L1 gene expression. In line with this
observation, coadministration of pevonedistat and anti-PD-L1
antibody induces synergistic effect in suppression of GBM cancer
cell growth in an animal model. Thus, our work presents a proof-
of-concept study for the evaluation of PD-L1/PD-1 blockade with
pevonedistat in GBM.
Methods
Cell lines, cultures and reagents
Human GBM cell lines U87, the stable red fluorescent protein
(RFP) expressing U87 cells, T98G cells and mouse glioma GL261
cells were obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA), and cultured in Dulbecco’s Modi-
fied Eagle’s Medium (Hyclone, Logan, UT, USA) containing 10%
fetal bovine serum (Biochrom AG, Berlin, Germany) and 1%
penicillin/streptomycin solution at 37C with 5% CO2. All cell lines
were tested and free of mycoplasma contamination. MG132 were
dissolved in dimethyl sulfoxide. For in vitro studies, pevonedistat
was dissolved in dimethyl sulfoxide, while pevonedistat was freshly
dissolved in 10% HPBCD (2-hydroxypropyl-β-cyclodextrin) and
stored in dark for in vivo studies.
Antibodies and immunoblotting
For direct Western blotting analysis, cells were lysed in RIPA
buffer with proteinase and phosphatase inhibitors. The antibodies
used were as follows: human PD-L1 (Cell Signaling, Beverly, MA),
mouse PD-L1 (R&D Systems, Minneapolis, MN, USA), NEDD8
(Cell Signal, Beverly, MA), NAE1 (Sigma, St. Louis, MO, USA),
UBA3 (Epitomics, Inc., Burlingame, CA, USA), UBE12/UbE2M
(Abcam, Cambridge, MA, USA), Cullin1 (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA, USA), Cullin3 (Cell Signal, Beverly, MA),
FBXW7 (Bethyl Laboratories, Montgomery, TX, USA), c-MYC
(Cell Signaling, Beverly, MA), FLAG (Sigma, St. Louis, MO, USA)
and β-actin (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
RNA isolation, first strand cDNA synthesis and RT-qPCR
Total RNA was isolated from cells using the RNeasy Mini Kit
(Qiagen, Hilden, Germany). cDNA was obtained by reverse tran-
scription using the Maxima First Strand cDNA Synthesis Kit for RT-
qPCR (Thermo Fisher Scientific), according to the manufacturer’s
What’s new?
Inhibitors of neddylation, a posttranslational modification that adds the ubiquitin-like NEDD8 protein to target proteins, are
promising cancer therapeutics, but might enhance cancer-associated immunosuppression. Here the authors show that
neddylation inhibitor pevonedistat upregulates programmed death ligand 1 (PD-L1) expression on glioblastoma cell lines
through stabilization of the c-Myc transcription factor. Blockade of the PD-L1/PD-1 interaction potentiates the effect of
pevonedistat on glioblastoma cell survival, providing proof-of-concept evidence for combining pevonedistat and PD-L1/PD-
1-blocking antibodies in future clinical trials.
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instructions. Relative mRNA levels were normalized to GAPDH
mRNA levels. Primer sets used were as follows: CD274-Forward:
ATTTGGAGGATGTGCCAGAG; CD274-Reverse: CCAGCACA
CTGAGAATCAACA; GAPDH-Forward: AAGGTGAAGGTCG
GAGTCAA; GAPDH-Reverse: AATGAAGGGGTCATTGATGG.
Cell surface PD-L1 detection
Cells were trypsinized and resuspended in 100 μL of cell
staining buffer (#420201, BioLegend, San Diego, CA, USA) and
incubated with APC-conjugated anti-human PD-L1 antibody
(#329708, BioLegend) for 1 hr at room temperature. Stained
cells were washed in the staining buffer and analyzed by fluo-
rescence assisted cell sorting (FACS) (BD Biosciences). The
PD-L1 expression levels on the cell surface were analyzed in
FlowJo 7.6.
ChIP assay
U87 cells were treated with or without pevonedistat for 48 hr and
fixed by adding formaldehyde (Fisher) into the culture medium to
a final concentration of 1%. Cross-linking was allowed to proceed
for 15 min and stopped by addition of glycine (0.125 M). Fixed
cells were washed with PBS and resuspended in IP Buffer
(100 mM Tris at pH 8.6, 0.3% SDS, 1.7% Triton X-100 and 5 mM
EDTA). Cells were sonicated with a 1/4-inch-diameter tapered
probe for 30 sec in a Branson 250 sonicator to produce genomic
DNA fragments (100~400 bp). Samples were immunoprecipitated
overnight at 4C with polyclonal antibody specific for c-MYC
(2 μg N262, Santa Cruz) and protein A beads. Beads were washed/
eluted and phenol/chloroform-extracted and ethanol-precipitated.
DNA was resuspended in 100 μL of water and applied for qPCR
analysis. PD-L1 promoter DNA fragment enrichment was ana-
lyzed by qPCR. PD-L1 promoter primers for qPCR-Forward:
GCTTTAATCTTCGAAACTCTTCCC, Reverse: CCTAGGAAT
AAAGCTGTGTATAGAAATG.
In vivo ubiquitination assay
The U87 cells were transfected with His-ubiquitin and FLAG-
PD-L1 as well as scramble or Cullin3 siRNA. 48 hr post-trans-
fection, cells were treated with 10 μM MG132 for 4 hr and lysed
in buffer A (6 M guanidine-HCl, 0.1 M Na2HPO4/NaH2PO4
and 10 mM imidazole [pH 7.5]). After sonication, the lysates
were incubated with Ni-NTA beads (QIAGEN) for 4 hr at room
temperature. The His pull-down proteins were washed twice
with buffer A and then twice with buffer A/B (1 volume buffer
A and 3 volumes buffer B), and one time with buffer B (25 mM
Tris–HCl and 20 mM imidazole [pH 6.8]). The pull-down sam-
ples were resolved by 2 × SDS-PAGE for immunoblotting.
PD-1 binding assay
The U87 and T98G cells were treated with or without
pevonedistat for 48 hr, then cells were trypsinized and incu-
bated with 2 μg/mL recombinant human PD-1 FC chimera
protein (#1086-PD-050, R&D Systems, Minneapolis, MN,
USA) at room temperature for 30 min. Cells were extensively
washed in staining buffer and further incubated with anti-
human Alexa Fluor 488 dye conjugated antibody (Thermo
Fisher Scientific) at room temperature for 30 min. Cells were
analyzed by FACS after wash in the staining buffer, and the
FACS data were analyzed using FlowJo 7.6.
T cell killing assay
The U87-RFP human glioma cells were seeded in a 24-well plate
with or without pevonedistat for 24 hr. Human peripheral blood
mononuclear cells (PBMC; #70025, STEMCELL, Vancouver,
WA, Canada) were activated with CD3 antibody (50 ng/mL),
CD28 antibody (50 ng/mL), and IL2 (10 ng/mL) (#317303;
#302913; #589102, BioLegend) and then co-cultured with
U87-RFP cells at 10:1 ratio. After 24 hr, U87-RFP cells were
sorted by FACS and subjected to clonogenic assay. After 10 days,
the colonies were stained with 0.5% crystal violet and counted
using a stereomicroscope.
Xenograft studies
All animal studies were approved by Zhengzhou University
Animal Care and Use Committee and performed in accor-
dance with guidelines. U87 or T98G (2 × 106) cells were
injected into the bilateral dorsal flanks of female nude mice
(6–8 weeks). When tumor volume reached approximately
60 mm3, mice were administered pevonedistat i.p. at a dose of
30 mg/kg 5 days per week for 3 weeks (as shown in Fig. 2a).
Tumors were collected after final treatment and applied for
immunoblotting and immunohistochemistry (IHC) analysis.
IHC staining of tumor tissue samples
U87 and T98G xenografted tumors in nude mice were formalin-
fixed, embedded in paraffin. Sections of 4-μm thick were cut and
incubated with 3% H2O2 for 15 min at room temperature to
block endogenous peroxidase activity. After incubating in normal
goat serum for 1 hr to block nonspecific binding of IgG, sections
were treated with primary antibody (PD-L1, clone E1L3N, Cell
Signaling) at 4C overnight. Sections were then incubated for
30 min with biotinylated goat-anti-mouse IgG secondary anti-
bodies (Fuzhou Maixin Biotech, Fuzhou, Fujian, China), followed
by incubation with streptavidin-conjugated HRP (Fuzhou Maixin
Biotech) and were developed with 3,30-diaminobenzidine
(Fuzhou Maixin Biotech). Images were taken using an Olympus
microscopic camera and matched software. To analyze and mea-
sure the IHC PD-L1 expression from U87 and T98G xenografts,
the stained slides were digitally scanned using the Aperio Scan-
Scope AT2 slide scanner (Leica Biosystems, Wetzlar, Germany)
and were captured with a 20× objective. The images were visual-
ized using ImageScope software (Leica Biosystems) and analyzed
by two pathologists (W.W. and Y.M.) using Aperio Image Tool-
box analysis software (Leica Biosystems). Cellular membranous
PD-L1 IHC expression on U87 and T98G xenografted tumor
cells was considered as positive PD-L1 expression. The intensity
scored as 0 (no staining), 1+ (weak staining), 2+ (moderate
staining), 3+ (strong staining) and extension (percentage) of
Zhou et al. 765
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expression were determined in each image. PD-L1 H-score from
each image was determined by multiplying the staining intensity
and the percentage of positive cells (a range of 0–300).
IHC analysis for Ki-67 was performed on the formalin-fixed
paraffin-embedded allograft samples with anti-Ki-67 rabbit
monoclonal antibody (mAb) (30-9, Ventana, Tucson, AZ, USA).
Five randomly selected, nonoverlapping images (20× objective)
were acquired for each specimen (three independent animals per
genotype). Ki-67-positive cells and total cells were manually
counted for each image, and the staining was quantified by cal-
culation the percentage of Ki-67 positive cells.
PD-L1 antibody and pevonedistat treated syngeneic tumor
model
C57BL/6 mice (6–8-week-old female) were subcutaneously
injected with 1 × 107 GL261 cells. Seven days after the injection
of tumor cells, mice were randomly divided into four groups
with comparable average tumor size: IgG control antibody
treatment, pevonedistat treatment, αPD-L1 treatment and
pevonedistat plus αPD-L1 treatment. Mice were injected intra-
peritoneally with 15 mg/kg pevonedistat or vehicle daily for a
total of 15 injections. In addition, 75 μg anti-mouse PD-L1
antibody (10F.9G2, Bio X Cell, West Lebanon, NH, USA) or
control rat IgG2b (LTF-2, Bio X Cell) were injected intraperito-
neally every 4 days for a total of 5 injections (as shown in
Fig. 5a). Tumor volumes were measured every 4 days and were
calculated using the formula: length × width2 × 0.5. Statistical
analysis was conducted using the GraphPad Prism software.
Statistical analysis
All data are represented as the mean  SD. The statistical signifi-
cance of differences between groups was assessed using GraphPad
Prism6 software with the Student t-test or one-way ANOVA. The
unpaired two-tailed t-test was used for comparing parameters
between groups. Three levels of significance (*P < 0.05,
**P < 0.01 and ***P < 0.001) were used for all tests.
Results
Genetic or pharmacological inhibition of neddylation
pathway enhances PD-L1 expression in vitro
To determine whether inhibition of neddylation pathway affects
PD-L1 protein level in GBM cells, we treated U87 and T98G
cells with siNAE1, siUBA3 or siUBC12, and determined PD-L1
protein expression by immunoblotting. Depletion of neddylation
pathway enzymes NAE1, UBA3 or UBC12 markedly increased
the total level of PD-L1 in both cell lines (Fig. 1a and Fig. S1a).
Mature PD-L1 expressed at the surface of cancer cells exerts
immunosuppressive effects by binding to PD-1 glycoprotein
receptor on activated T cells.21 To further determine whether
the cell surface PD-L1 level is upregulated upon silencing of
these neddylation pathway enzymes, cells transfected with non-
targeting siRNA, siNAE1, siUBA3 or siUBC12 were subjected
to flow cytometry using fluorescence-labeled PD-L1 antibody.
Knocking down of any individual neddylation enzymes significantly
elevated the cell surface PD-L1 levels in both human GBM cell
lines (Fig. 1b and Fig. S1b). The key physiological substrates
of neddylation are cullin family numbers, which regulate hun-
dreds of protein stability, including PD-L1.22 Interestingly, the
mRNA of PD-L1 was upregulated after cells were depleted of
neddylation enzymes, indicating inhibition of neddylation
pathway also transcriptionally increases PD-L1 levels (Fig. 1c
and Fig. S1c). In addition, in the murine GBM cell line
GL261, we also assessed PD-L1 protein level upon silencing of
neddylation pathway enzymes. Neddylation enzyme-depleted
GL261 cells exhibited higher PD-L1 expression compared to
control cells (Fig. 1d).
Pevonedistat, the neddylation pharmacological inhibitor,
forms a covalently bound adduct with NEDD8 while bound
to NAE and inhibits protein neddylation.6,23 In order to
examine the effect of pevonedistat on PD-L1 protein levels,
we treated U87 cells with either pevonedistat or proteasome
inhibitor MG132. Both inhibitors markedly increased the
overall protein level of PD-L1 (Fig. 1e). Consistent with the
results, pevonedistat and MG132 are both able to elevate cell
surface PD-L1 levels in U87 and T98G cells (Fig. 1f and
Fig. S1d). Interestingly, in line with the neddylation enzyme
depletion results, pevonedistat induced PD-L1 mRNA levels in
both the cell lines, while MG132 treatment did not show any sig-
nificant changes in PD-L1 transcripts (Fig. 1g). The similar effect
of pevonedistat on murine GL261 cells was shown in Figure 1h.
Together, these results indicated that genetic and pharmacologic
inhibition of the neddylation pathway upregulates PD-L1
expression in GBM cells.
Pevonedistat enhances PD-L1 expression in vivo
We next sought to examine whether pevonedistat may affect
PD-L1 expression in tumors. Mice bearing U87 and T98G cells
were treated with pevonedistat 5 days a week for 3 weeks
(Fig. 2a). Tumor tissues from xenografts were harvested and sub-
jected to qPCR analysis for the expression of PD-1 mRNA and
immunoblotting with PD-L1 antibody. As shown in Figure 2b
and Figure S2a, PD-L1 mRNA levels were significantly elevated
upon pevonedistat treatment in U87 and T98G xenografts as
compared to control. Consistently, PD-L1 protein levels are
much higher in the pevonedistat-treated tumors compared to
control tumors (Fig. 2c and Fig. S2b). In line with the results, we
also found increased PD-L1 protein staining in the tumors from
mice administered with pevonedistat relative to untreated
tumors (Figs. 2d and 2e; Figs. S2c and S2d). These in vivo results
substantially support the conclusion that inhibition neddylation
pathway by pevonedistat leads to PD-L1 upregulation in GBM
tumors.
Cullin1-FBXW7/c-MYC axis mainly contributes to the PD-L1
induction in GBM cells
The cullin family members of cullin-RING Ligases are the major
substrates for NEDD8 conjugation (neddylation).24,25 Zhang and
colleagues recently investigated the potential interaction between
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Figure 1. Inhibition of neddylation pathway increases PD-L1 expression in glioblastoma cells in vitro. (a) Depletion of neddylation pathway
enzymes (NAE1, UBA3 or UBC12) markedly increased PD-L1 protein levels in U87 cells. (b) The U87 cells treated with NAE1, UBA3 or UBC12
siRNA were subjected to FACS analysis for cell surface PD-L1 expression. (c) Silencing of neddylation pathway enzymes upregulates PD-L1
mRNA expression. (d) Mouse glioma GL261 cells were transfected with siRNA targeting Nae1, Uba3 or Ubc12 for 72 hr. Mouse PD-L1 protein
levels were detected by Western blotting. (e) U87 cells were treated with pevonedistat (1 μM) or MG132 (1 μM) for 24 hr. PD-L1 protein was
examined by Western blotting. (f ) Cell-surface expression of PD-L1 was examined by using flow cytometry upon treatment with pevonedistat
or MG132 (left), and the quantification of PD-L1 expression was shown (right). (g) PD-L1 mRNA expression was analyzed by qPCR in U87 cells
treated with pevonedistat or MG132 for 24 hr. (h) PD-L1 was upregulated in GL261 cells with either pevonedistat or MG132 treatment. [Color
figure can be viewed at wileyonlinelibrary.com]
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cullin protein and PD-L1. They found that PD-L1 is able to bind
to both Cullin1 and Cullin3, but the interaction is stronger with
Cullin3.22 Thus, we detected the PD-L1 protein levels upon
silencing of Cullin1 or Cullin3. Consistently, we observed higher
protein levels of PD-L1 in both Cullin1- and Cullin3-depleted
U87 and T98G cells (Fig. 3a and Fig. S3a). Surprisingly, we
found much higher upregulation of PD-L1 in the cells with
silencing of Cullin1 relative to that in the cells with Cullin3
knockdown (Fig. 3a and Fig. S3a). Similar results were observed
for the PD-L1 protein levels on the cell surface in both cell lines,
which support the conclusion that PD-L1 expression is associ-
ated with Cullin1 protein levels in GBM cells (Fig. 3b and
Fig. S3b). The half-life of oncoprotein c-MYC is mainly regulated
by Cullin1-FBXW7 E3 ligase, and importantly c-MYC is recently
identified as a key transcriptional activator of PD-L1 gene by
directly binding to PD-L1 promoter region.26 Therefore, we next
examined the effect of FBXW7 depletion on PD-L1 mRNA and
protein levels in two GBM cell lines. As expected, knockdown of
FBXW7 led to the accumulation of c-MYC oncoprotein, as well
as the elevation of PD-L1 mRNA and protein levels in both U87
and T98G cells (Figs. 3c and 3f ). In line with these results, deple-
tion of FBXW7 also elevated the protein abundance of cell surface
PD-L1 (Figs. 3g and 3h). Moreover, we used chromatin immuno-
precipitation (ChIP) to evaluate c-MYC-dependent PD-L1 gene
transcription upon FBXW7 silencing. As shown in Figure 3i,
the binding of c-MYC to the PD-L1 promoter region was sig-
nificantly increased in siFBXW7-treated U87 cells relative to
control cells.
To further explore whether the negative regulation of PD-L1
expression by FBXW7 is through c-MYC, we co-transfected the
U87 cells with FBXW7 and c-MYC siRNAs and examined the
total and cell surface PD-L1 protein levels by immunoblotting
and flow cytometry. In support of our hypothesis, depletion of
c-MYC markedly abrogated the upregulation of both PD-L1
mRNA and protein in FBXW7-knocked down cells (Figs. 3j
and 3l). Consistent with the results in U87 cells, similar effect
Figure 2. Neddylation inhibitor pevonedistat induces PD-L1 expression in vivo. (a) A schematic of the treatment plan for nude mice bearing
subcutaneous U87 tumors. Female nude mice were implanted with 1 × 107 U87 cells subcutaneously and received neddylation inhibitor
pevonedistat treatment. (b) Human PD-L1 mRNA expression was analyzed by qPCR in U87 xenografts treated with pevonedistat or vehicle.
(c) U87 tumors were isolated, and total proteins were prepared to evaluate PD-L1 expression by immunoblotting. (d, e) U87 tumors were also
subjected to IHC for the detection of PD-L1 and quantification for PD-L1 staining. Scale bar, 20 μm. [Color figure can be viewed at
wileyonlinelibrary.com]
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Figure 3. Neddylation inhibition-induced PD-L1 upregulation is mainly attributed by Cullin1-FBXW7/c-MYC axis. (a) U87 cells were transfected
with siCullin1 or siCullin3 for 72 hr. The cell lysates were applied to SDS-PAGE for detection of PD-L1 proteins by immunoblotting. (b) Flow
cytometry analysis and quantification of cell surface PD-L1 protein levels on the U87 cells with depletion of Cullin1 or Cullin3.
(c, e) Immunoblotting analysis of c-MYC and PD-L1 expression in both U87 and T98G cells upon knockdown of E3 ubiquitin ligase FBXW7.
(d, f ) qPCR analysis of the PD-L1 mRNA levels in both U87 and T98G cells upon knockdown of FBXW7. (g, h) U87 and T98G cells were treated
with scramble or FBXW7 siRNA for 72 hr. The cells were harvested for flow cytometry analysis to detect and quantify cell surface PD-L1
protein levels. (i) ChIP assay to detect the physical interaction of c-MYC and PD-L1 promoter region upon transfection of FBXW7 siRNA. ( j) Co-
transfection of c-MYC siRNA rescued FBXW7 silencing-induced upregulation of PD-L1 expression in U87 cells by immunoblotting analysis.
(k) qPCR analysis of the PD-L1 mRNA levels in U87 cells upon treatment of siCtrl, siFBXW7, sic-MYC or sic-MYC+siFBXW7. (l) Cell surface PD-L1
proteins were downregulated upon c-MYC siRNA co-transfection in U87 cells with depletion of FBXW7. [Color figure can be viewed at
wileyonlinelibrary.com]
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of c-MYC silencing on FBXW7 knockdown-induced PD-L1
mRNA and protein upregulation was observed in T98G cells
(Figs. S3c–S3e). Cullin3-SPOP E3 ligase is shown to be the
physiological E3 ubiquitin ligase for PD-L1.22 Consistent with
this notion, we were also able to detect relatively lower intensity
of polyubiquitinated PD-L1 signals in the cells treated with siC-
ullin3 (Fig. S3f). Taken together, our results indicate that
Cullin1-FBXW7/c-MYC axis contributes to the upregulation of
PD-L1 expression in GBM cells.
Inhibition of neddylation pathway attenuates T cell killing
through PD-L1 induction
In order to examine whether pevonedistat-induced PD-L1
upregulation has physiological function, we first explored the
Figure 4. Pevonedistat attenuates T cell killing through PD-L1 induction. (a) FACS analysis of cell surface PD-1 binding of U87 cells upon
treatment of 1 μM pevonedistat for 48 hr. (b) Quantification of PD-1 binding to cell surface of U87 cells treated with dimethyl sulfoxide or
1 μM pevonedistat. (c) U87 cells expressing RFP protein were first treated with or without pevonedistat (1 μM) for 12 hr and then
cocultured with or without activated PBMCs. After 48 hr, U87-RFP cells were sorted by flow cytometry and applied for clonogenic assay.
(d) Quantification of relative surviving colonies in the indicated four groups: control, pevonedistat treatment, PBMC treatment, co-treatment
of pevonedistat and PBMC. (e) U87-RFP cells were treated with or without pevonedistat (1 μM) for 12 hr and then cocultured with activated
PBMCs in the presence or absence of anti-PD-L1 antibody (10 μg/mL) for 48 hr. U87-RFP cells were then sorted by flow cytometry and applied
for clonogenic assay. (f ) Quantification of relative colony numbers in the indicated groups of (e). [Color figure can be viewed at
wileyonlinelibrary.com]
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binding intensity of PD-1 on GBM cells. Upon incubation of
recombinant PD-1 protein with U87 cells, the binding of PD-1 on
the cell surface was significantly increased in the pevonedistat-
treated cells compared to the control cells (Figs. 4a and 4b). We
observed similar changes in T98G cells with pevonedistat treat-
ment (Figs. S4a and S4b). The inhibitory signals mediated by PD-1
play a major role in T cell inactivation, exhaustion during cancer
development.27,28We next sought to determine whether inhibition
of neddylation pathway affects T cell function. To this end, we
cocultured U87-RFP (red fluorescence) cells with activated human
PBMCs in the presence or absence of pevonedistat. After 48 hr, the
U87-RFP cells were sorted using flow cytometry and subjected to
clonogenic formation assay. As expected, pevonedistat and T cells
efficiently inhibited the clonogenic cell survival. Interestingly,
U87-RFP cells co-administrated of both pevonedistat and T
cells demonstrated similar surviving clones compared to PBMC
treatment alone, indicating that pevonedistat treatment might
block the cytolytic effect of T cells (Figs. 4c and 4d). Based on
these results, we further explore the impact of the combination
of anti-PD-L1 antibody and pevonedistat on the GBM cell sur-
vival in the PBMC-mediated cell killing assay. As shown in
Figures 4e and 4f, blockade of PD-L1/PD-1 interaction by
PD-L1 antibody sensitized pevonedistat-treated U87-RFP cells
to activated PBMC-induced cell killing. Hence, these above
results indicated that inhibition of neddylation pathway by
pevonedistat in GBM cells mitigates T cell-mediated cell death,
while PD-L1/PD-1 immune checkpoint inhibitors can reverse
pevonedistat-induced immune resistance.
Figure 5. Pevonedistat-induced suppression of anticancer immunity is abrogated by PD-L1 blockade in vivo. (a) A schematic of the treatment
plan for mice bearing subcutaneous GL261 tumors. Female C57BL/6 mice were implanted with 1 × 106 GL261 cells subcutaneously and
received one of four treatments: control antibody treatment, pevonedistat treatment, anti-PD-L1 antibody treatment or anti-PD-L1 antibody
plus pevonedistat combination treatment. (b) GL261 implanted tumor-bearing mice were randomly enrolled in different treatment groups as
indicated. For each treatment group, tumor volumes were measured every 4 days and plotted individually. (c) Immunohistochemical Ki-67
staining and quantification of GL261 tumors in each treatment group. Scale bar, 50 μm. (d) Percentage quantification of Ki-67 positive cells in
(c). (e) GL261 tumors from control and pevonedistat-treated groups were isolated to evaluate mouse PD-L1 protein expression by
immunoblotting. (f ) The intensity of mouse PD-L1 protein levels was quantified and plotted for control and pevonedistat-treated groups.
[Color figure can be viewed at wileyonlinelibrary.com]
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Pevonedistat-induced suppression of anticancer immunity is
abrogated by PD-L1 blockade in vivo
Clinical investigations showed that the efficacy of anti-PD-L1/
PD-1 immunotherapy correlates with tumor cells-associated
PD-L1 protein levels.29,30 Given pevonedistat-induced PD-L1
upregulation in GBM tumor cells, we hypothesized that inhibi-
tion of neddylation pathway by pevonedistat might synergize
with PD-L1 blockade to enhance therapeutic effect. We therefore
treated immuno-proficient mice bearing GL261 tumors with
pevonedistat and anti-PD-L1 alone or in combination (Fig. 5a).
In line with our observations in vitro, pevonedistat plus PD-L1
blockade antibody markedly retarded GL261 tumor progression
relative to the growth restriction by each agent alone (Fig. 5b).
However, we did not find any obvious changes in body weight
of these four different treatment groups (Fig. S5). Additionally,
Ki-67 positive stained tumor cells were significantly fewer in the
combined treatment group compared to each treatment alone
(Figs. 5c and 5d). In line with the observation in Figure 2, mouse
PD-L1 expression was significantly elevated upon pevonedistat
treatment in this allograft mouse model (Figs. 5e and 5f ), which
further validated that protein neddylation inhibitor-mediated
the PD-L1 upregulation is the molecular basis of this synergistic
effect. These results suggested that PD-L1 blockade potentiates
the therapeutic effect of pevonedistat by abrogating the acquired
tumor-associated immunosuppression in GBM.
Discussion
As a promising anticancer agent, pevonedistat is currently in mul-
tiple Phase I/II clinical trials for both solid tumors and hematologi-
cal malignancies.31–34 Overactivation of the neddylation pathway
has been observed in majority of samples in a GBM tumor cohort
compared to normal tissues.5 Inhibition of neddylation pathway
by pevonedistat as a potential therapeutic strategy has been vali-
dated in both GBM cancer cells in vitro and an orthotopic xeno-
graft mouse model in vivo.5 In addition, pevonedistat might have
its advantage over other agents regarding penetrating the blood
brain barrier, since pevonedistat is a small molecule inhibitor with
low molecular weight and high solubility in lipid. Although the
cytotoxic effects of pevonedistat, including inducing cell-cycle
arrest, apoptosis and autophagy, have been well studied, the role of
neddylation inhibition in cancer-associated immunity remains
largely unknown. Glioblastoma usually establishes an immuno-
suppressive tumor microenvironment in the brain, which helps
the lesion growth and becomemalignant through evading immune
system.35–37 Thus, immunotherapy to counteract immune evasion
and suppression has already been underway in a few preclinical
and clinical studies in GBM.18,38–40 The scientific basis from our
study is able to help testing the efficacy of the combination of
pevonedistat and PD-L1/PD-1 antibody in GBM by leveraging the
advantages of two powerful anticancer agents. Thus, the synergistic
effect of pevonedistat and anti-PD-L1/PD-1 needs to be investi-
gated in an orthotopic model in future studies.
Our studies suggest that simultaneous inhibition of neddylation
pathway and PD-L1 may benefit GBM patients. Therefore, the
highly active status of the neddylation pathway in GBM patients
might serve as a biomarker for the standard of patient population
enrollment in clinical trials for the combination treatment of
pevonedistat and immune checkpoint inhibitors. Moreover, our
results also indicate that inhibition of Cullin1-SKP1-FBXW7 E3
ligase activity and thereby accumulation of c-MYC protein by
pevonedistat leads to PD-L1 upregulation (Fig. 6). Therefore, the
expression levels or mutation status of FBXW7 and c-MYC
proteins might also reflect the therapeutic efficacy of the combina-
tion treatment. Indeed, both loss-of-function (mutations or dele-
tion) of tumor suppressor FBXW7 and overexpression of c-MYC
oncoprotein correlate with PD-L1 expression levels and poor prog-
nosis in some malignancies.41,42 Therefore, whether anti-PD-L1/
PD-1 immunotherapy induces better effect in GBM patients with
FBXW7 inactivation and/or MYC activation remains further
investigation.
Inhibition of neddylation by pevonedistat has been shown
to suppress the release of some proinflammatory cytokines by
dendritic cells such as TNF-α and IL-6, and mitigates dendritic
NAE1
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c-MYC
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Figure 6. Synergistic effect of pevonedistat and PD-L1/PD-1 blockade in
the treatment of GBM tumors. A working model of how PD-L1 protein
level is regulated by the neddylation pathway in GBM cells. Genetic and
pharmacologic inhibition of neddylation pathway upregulates PD-L1
expression largely through abrogating the E3 ubiquitin ligase activity of
SKP1-Cullin1-FBXW7 complex, which thereby stabilize a key oncoprotein
substrate c-MYC. C-MYC directly binds to the promoter region of PD-L1
gene and transcriptionally activates PD-L1 expression. At the same time,
inhibition of neddylation pathway is able to attenuate Cullin3 ubiquitin
ligase activity, which in turn prolongs the half-life of PD-L1 protein.
Therefore, the rise in PD-L1 might be one of the underlying mechanisms
accounting for pevonedistat resistance via evasion of immune
surveillance checkpoints. Our work provides a molecular mechanism as
well as the rationale for the combination of neddylation pathway
inhibitor pevonedistat and PD-L1 blockade treatment as a more efficient
anticancer therapeutic strategy in future. [Color figure can be viewed at
wileyonlinelibrary.com]
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cells-mediated T cell stimulation.43 However, in our study, we
could observe PD-L1 blockade potentiates pevonedistat in vitro
and in vivo, indicating that anti-PD-L1 successfully reverses
pevonedistat-induced T cell inactivation. Careful attention
should be paid to the dose and dosing regimen in future studies
to prevent “over-inhibition” of T cell function by pevonedistat.
Taken together, the interaction between neddylation pathway
and PD-L1 as shown in our study is timely for developing more
effective combination therapies in GBM.
In summary, we in our study demonstrated that pevonedistat
markedly upregulates PD-L1 expression primarily through inactiva-
tion of Cullin1 and Cullin3 activity, which in turn transcriptionally
drives PD-L1 gene expression by dysregulated Cullin1-FBXW7/
c-MYC axis and stabilizes PD-L1 protein by decreased Cullin3 E3
ubiquitin ligase activity. Therefore, pevonedistat renders GBM cells
more resistant to cytolysis induced by T cells, whereas blockade of
PD-L1 successfully potentiates pevonedistat in vitro and in vivo.The
results of this work provided a scientific rationale for clinical trials of
coadministration of pevonedistat and anti-PD-L1/PD-1 in GBM
patients in future.
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